Please read and agree to the terms and conditions of this site.
@techcrunch.com 2 years ago
Flagship Pioneering’s new venture is betting on tRNA to treat “thousands of diseases”
@xconomy.com 3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com 3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com 3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com 4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com 4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com 4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com 4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com 4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com 4 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com 4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com 5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com 5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@techcrunch.com 5 years ago
CB Therapeutics’ lab-grown cannabinoids could unlock new medicines and make others affordable
@xconomy.com 5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com 5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@techcrunch.com 6 years ago
Reverie Labs uses new machine learning algorithms to fix drug development bottlenecks